Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC's endorsement guide to come later in 2009

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission will issue updated guides later in 2009 to assist advertisers in using endorsements. Agency staff is currently analyzing comments about proposed changes to its 1980 guides, said David Vladeck, director of FTC's Bureau of Consumer Protection (1"The Tan Sheet" Dec. 1, 2008). The current "guides are not working as intended to prevent consumer deception," particularly with "typicality claims," he told the Senate Consumer Protection, Product Safety, and Insurance Subcommittee July 22. Vladeck said testimonials and endorsements still are misused, particularly with weight-loss products

You may also be interested in...



FTC charges weight-loss product marketers

The Federal Trade Commission underscores that dietary supplement weight-loss claims are a top enforcement priority by charging three companies and two individuals with making false claims for diet products Relacore and Akavar 20/50. The commission seeks restitution from Basic Research, Carter-Reed, Dynakor Pharmacal and company executives Dennis Gay and Mitchell Friedlander. The suit, filed in U.S. District Court for the District of Utah, also alleges Basic Research, Gay and Friedlander violated a previous order from 2006 not to make bogus claims. The violation occurred when they advertised Relacore and Akavar as allowing users to "eat all you want and still lose weight." The case drives home the message David Vladeck, director of the Bureau of Consumer Protection, delivered in July when he said supplement weight-loss claims are a "high priority" for FTC because "false claims engender false hopes" (1"The Tan Sheet" Aug. 3, 2009)

FTC Testimonial Guidelines Say Advertisers Must Show Typical Outcomes

Revised Federal Trade Commission guidelines on endorsements and testimonials will not have a chilling effect on advertising as long as marketers using anecdotal testimonials provide information on what typical outcomes are, according to an FTC executive

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Topics

UsernamePublicRestriction

Register

PS103183

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel